Drug
bortezomib
2 HCP commentary reports on clinical trials studying bortezomib. Each report covers what clinicians said in public about one trial, with the source behind every view.
| Trial | Indication | Phase | Statements | HCP sources | Size | Updated | Preview |
|---|---|---|---|---|---|---|---|
| EXCALIBER-RRMM NCT04975997 · Celgene | Multiple myeloma | Phase 3 | 664 | 52 | Deep | Oct 18, 2026 | Preview |
| EAA181 NCT04566328 · ECOG-ACRIN Cancer Research Group | Multiple myeloma | Phase 3 | 352 | 101 | Deep | Oct 18, 2026 | Preview |